MedTrace Logo

Nesiritide in Resistant Hypertension

NCT01514357 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-03-23

Study results available
· View outcomes & findings →

Summary

Hypothesis: If the use of B-type natriuretic peptide (BNP) is proven to be effective in controlling high blood pressure, it may lead to a reduction of standard therapy and improved cardiovascular and kidney protection.

Conditions

Interventions

DRUG

Nesiritide (BNP)

NATRECOR® (nesiritide) is a sterile, purified preparation of human B-type natriuretic peptide (hBNP), and is manufactured from E. coli using recombinant DNA technology. Each 1.5 mg vial contains a white- to off-white lyophilized powder for intravenous (IV) administration after reconstitution.

DRUG

Placebo

Placebo will be administered subcutaneously instead of active drug (nesiritide) in a blind fashion in the second arm of the study.

Sponsors & Collaborators

  • National Center for Research Resources (NCRR)

    collaborator NIH

  • John C Burnett

    lead OTHER

Principal Investigators

  • John C Burnett, M.D. · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2014-07-31
Completion
2014-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01514357 on ClinicalTrials.gov